We are no longer just hoping for breakthroughs in Alzheimer’s disease, we are seeing them become a reality. From advanced diagnostics that could save precious time, to new ways of crossing the blood brain barrier and delivering medicines directly to the brain, the landscape is shifting. #Alzheimers #Neuroscience #BrainHealth
About us
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
External link for Roche
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Switzerland 🇨🇭
- Type
- Public Company
- Specialties
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data, and Science
Locations
Employees at Roche
Updates
-
What if sustainability became the starting point for your next big idea? 🌍💡 Real challenges, real teams, real responsibility. We're thrilled to welcome more than 60 interns from over 20 countries to our Global Internship Programme in Innovation & Sustainability (#IP2TIS)! Over the coming months, they'll work on real projects across Science & Innovation, Digital, Technology & AI, Society and Sustainability - transforming ideas into solutions that matter. Because meaningful impact isn't defined by years of experience. It's created when you're trusted to contribute, supported to grow, and empowered to make a difference. To our new #IP2TIS interns: We can't wait to see the future you'll help shape 🌱 Curious? See what #IP2TIS is all about. https://lnkd.in/dqVQZF3R #Roche #IP2TIS #RocheCareers #Innovation #Sustainability #TakeAction
-
Every milestone reflects our shared commitment to improving patients' lives. By advancing science and innovation, we continue doing now what patients need next. Thank you to our teams around the world whose dedication makes this possible. Read our CEO Thomas Schinecker's message below to learn more.
As we report our half-year results today, our strong momentum continued, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development. What matters most is the progress we make for patients. We shared positive phase III data for a potential best-in-class therapy in advanced lung cancer. In addition, our regulatory progress accelerated with five US FDA Priority Reviews — including in early-stage breast cancer, thyroid eye disease, colon cancer and autoimmune kidney disease. In Diagnostics, we reached major milestones with the launch of our new sequencing solution, alongside European CE marks for key diagnostic tests in Alzheimer’s pathology and latent tuberculosis screening. With several exciting launches on the horizon and strong momentum across our entire business, together, we continue to push the boundaries of innovation to prevent, stop and cure diseases, making a meaningful difference in the lives of patients around the world. A big thank you to our employees, partners and customers!
-
Roche continues strong momentum with 6% sales growth (CER) in the first half of 2026 – full-year outlook confirmed. For more details on our performance, click here ➡️ https://spkl.io/60497JsLB
-
People living with haemophilia A deserve the freedom to participate fully in daily life without constant worry around bleeds and treatment burden. As their expectations of what holistic care looks like evolve, so too must the definition of progress in haemophilia A. Explore what meaningful care looks like today in the latest article by John Pasi MBE, Global Head of Haematology and Rare Blood Diseases at Roche 👉 https://spkl.io/60437J93P #HaemophiliaA #BleedingDisorders #PatientCare
Meaningful Care in Haemophilia
-
We join the scientific community worldwide in commemorating the remarkable life and contributions of Susumu Tonegawa, a molecular biologist whose pioneering research was fundamental to our comprehension of the human immune system. Dr. Tonegawa’s tenure at our Basel Institute for Immunology, 1972 to 1981, proved transformative. He took on a fundamental biological puzzle: how our bodies manage to produce a vast array of unique antibodies from a limited genetic template. By revealing the mechanism of gene recombination, he provided the key to understanding how our immune system recognises and defends against an endless variety of pathogens. This breakthrough on antibody gene segments, recognised with the 1987 Nobel Prize in Medicine, advanced basic biology and paved the way for modern immunological therapies, including the development of humanised antibodies that have fundamentally influenced the landscape of patient care. At Roche, we feel a meaningful connection to Dr. Tonegawa’s legacy and are proud to have been part of his scientific journey. We are inspired by his passion and drive to push the frontiers of science. His spirit of inquiry drives our own mission and commitment to trailblaze new scientific research. We honour his memory by carrying forward his passion for discovery, dedicated to turning complex biological insights into meaningful breakthroughs for patients worldwide.
-
-
Roche’s nanopore-based sensor module is the electronic heart of our sequencing by expansion (SBX) innovation. The module contains 8 million microscopic wells, each one spanned by a thin membrane with a single nanopore through which a single molecule can pass. SBX delivers clear, highly accurate DNA sequencing results with speed and efficiency. Learn more: https://lnkd.in/dH9WdQfr (Roche's sequencing technology is currently for research use only.) #NextGenSequencing #Genomics #RocheSBX #BiotechRND
-
Historically, the retina has been one of the most difficult organs to reach. This makes delivering treatments highly challenging, often forcing researchers to rely on slow, macro-structural changes to measure if a new therapy is working. Today, advancements in non-invasive retinal imaging are transforming this baseline. By allowing us to see the back of the eye directly at a cellular level, these technologies allow us to map these cellular changes in real time, accelerating early-stage in vivo validation for clinical studies/trials and building a more predictive data architecture for our pipelines. Below, Clinical Research Fellow Niamh Gould takes us #InsideRocheRnD to explain how we deploy these high-resolution imaging frameworks. #Ophthalmology #pRED #TranslationalMedicine #ScienceLife
-
Alzheimer’s disease can take away the moments that matter the most, but innovation is driving real progress. By transforming care at every stage of the #Alzheimers journey, we’re working to protect the memories and people who shape our lives. Hear from Amy VanBuskirk, Malú Gámez Tansey and Geoffrey Kerchner as they explain the latest breakthroughs that are shaping Alzheimer's and what they could mean for the future of patient care. 👇 #EarlyDiagnosis #Neuroscience #BrainHealth
-
Every blood transfusion represents more than a medical procedure—it represents a patient’s trust in the healthcare system. A critical aspect of this trust comes from the assurance of safe blood. In this thought-provoking article, Vaibhav Kohli, Vice President, Marketing, Access & Commercial Excellence at Roche Diagnostics India, explores the role of Nucleic Acid Testing (NAT) alongside serology and shares insights from emerging evidence on advancing blood safety in India. Read the article and join the conversation on how innovation in diagnostics can contribute to safer healthcare outcomes. #RocheDiagnosticsIndia | #ValueOfDiagnostics | #NAT | #BloodSafety
Every blood transfusion carries more than a unit of blood. It carries a patient's trust in our healthcare system. As diagnostic science continues to advance, so does our understanding of the gaps that can exist in standard blood donor screening. In my latest article, I explore why looking beyond conventional testing methods is critical, how Nucleic Acid Testing (NAT) complements serology, and what the latest 2026 evidence from India tells us about strengthening patient safety. Read the full perspective below and join the conversation on the future of safer blood screening. 👇 #RocheDiagnosticsIndia #ValueOfDiagnostics #NAT #BloodSafety #HealthcareLeadership